[Federal Register: June 18, 2009 (Volume 74, Number 116)]
[Notices]
[Page 28938-28939]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr18jn09-31]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60 Day-09-0595]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
Alternatively, to obtain a copy of the data collection plans and
instrument, call 404-639-5960 and send comments to Maryam I. Daneshvar,
CDC Reports Clearance Officer, 1600 Clifton Road NE., MS-D74, Atlanta,
Georgia 30333; comments may also be sent by e-mail to omb@cdc.gov.
Comments are invited on (a) whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarify of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of information technology. Written comments
should be received within 60 days of this notice.
Proposed Project
The Model Performance Evaluation Program for HIV Rapid Testing
(MPEP HIV-RT) (OMB Control No. 0920-0595, expiration date 3/31/2010)--
Revision--National Center for Preparedness, Detection, and Control of
Infectious Diseases (NCPDCID), Centers for Disease Control and
Prevention (CDC).
Brief Description and Background
To support CDC's mission of improving public health and preventing
disease through continuously improving laboratory practices, CDC is
requesting approval from the Office of Management and Budget (OMB) to
continue data collection activities of the HIV rapid testing
performance evaluation program (MPEP HIV RT) and to make changes to the
results form.
This program offers external performance evaluation (PE) twice a
year for rapid HIV tests approved by the U.S. Food and Drug
Administration (FDA). Examples of such tests are the OraQuick ADVANCE
Rapid HIV-\1/2\ Antibody Test, the Uni-Gold Recombigen HIV test, the
Clearview HIV \1/2\ STAT-PAK, the Clearview COMPLETE HIV \1/2\, and the
MedMira Reveal G3 Rapid HIV-1 Antibody Test. Participation in PE
programs is expected to lead to improved HIV testing performance
because participants have the opportunity to identify areas for
improvement in their testing practices. This program helps to ensure
accurate HIV rapid testing which is the foundation for HIV prevention
and intervention programs.
This program offers laboratories/testing sites opportunities for:
(1) Assuring that the laboratories/testing sites are providing
accurate test results through external quality assessment
(2) Improving testing quality through self-evaluation in a non-
regulatory environment
(3) Testing well characterized samples from a source outside the
test kit manufacturer
(4) Discovering potential testing problems so that laboratories/
testing sites can adjust procedures to reduce and eliminate errors
(5) Comparing individual laboratory/testing site results to others
at the national and international level, and
(6) Consulting with CDC staff to discuss testing issues.
Program participants receive PE samples twice each year and report
testing results to CDC. In addition to conducting the performance
evaluation, participants in the MPEP HIV Rapid Testing program are
required to complete a biennial (every other year) laboratory practices
questionnaire. The burden for the Laboratory Practices Questionnaire
has been adjusted for the average per year, since respondents complete
the survey every two years. CDC does not charge any fees to sites
participating in this external quality assessment program.
There is no cost to respondents to participate in this program.
[[Page 28939]]
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Respondents Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Labs............................................ 660 2 10/60 220
Labs............................................ 330 1 30/60 165
---------------------------------------------------------------
Total....................................... .............. .............. .............. 385
----------------------------------------------------------------------------------------------------------------
Dated: June 11, 2009.
Maryam I. Daneshvar,
Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. E9-14312 Filed 6-17-09; 8:45 am]
BILLING CODE 4163-18-P